FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion
- 1 January 1993
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 17 (3) , 301-307
- https://doi.org/10.1016/s0168-8278(05)80209-0
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Involvement of tumor necrosis factor-α in development of hepatic injury in galactosamine-sensitized miceHepatology, 1990
- Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat.Journal of Clinical Investigation, 1990
- CyclosporineNew England Journal of Medicine, 1989
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989
- Spontaneous production of tumor necrosis factor alpha by Kupffer cells of MRL/lpr mice.The Journal of Experimental Medicine, 1988
- Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor.The Journal of Experimental Medicine, 1987
- Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection.The Journal of Experimental Medicine, 1987
- Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells.The Journal of Experimental Medicine, 1987
- Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.The Journal of Experimental Medicine, 1986
- Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxinNature, 1984